Dec 18, 2020 13:09 JST

Source: Eisai

Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan

To Strengthen Its in-House Production Function for Formulating Anti-Cancer Agent Lenvima?

TOKYO, Dec 18, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced that it has completed construction of the 5th manufacturing building at the Kawashima Industrial Park located in Gifu Prefecture, Japan.

External views of the 5th manufacturing building

The 5th manufacturing building is a facility specifically designated for formulating anti-cancer drugs (total floor area: approximately 4,500m2). Since anti-cancer drugs are highly active, this building is designed to make it possible to manufacture anti-cancer agents more safely, with various preventive features for controlling highly active substances, such as preventing cross-contamination of agents and exposure to workers. Eisai plans to manufacture its in-house discovered and developed anti-cancer agent Lenvima, which are in increasing demand worldwide, at this facility from FY2021. We also secure space for further installation of manufacturing equipment for other anti-cancer drugs within this building. The total investment for the construction of the 5th manufacturing building is approximately 5 billion yen.

The Kawashima Industrial Park, opened in 1966, is Eisai?s global pharmaceutical manufacturing base. In addition, this Industrial Park is a role model factory for our global production activities, where we are making new progresses such as utilizing digital technology and new technologies. With the completion of the 5th manufacturing building, Eisai will further expand the stable supply system of high-quality pharmaceuticals in Japan, and continues further contribution to improve the benefits of patients and their families in Japan and around the world.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong
March 02 2021 08:06 JST
Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090
February 22 2021 14:40 JST
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy
February 22 2021 12:11 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
February 15 2021 10:07 JST
Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea
February 01 2021 08:35 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time
January 26 2021 10:58 JST
Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium
January 12 2021 11:37 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR
December 17 2020 11:47 JST
Eisai: Biogen Files New Drug Application for Aducanumab in Japan
December 11 2020 09:43 JST
Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium
December 04 2020 11:17 JST
More Press release >>

Latest Press Release

More Latest Release >>